Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K J Scanlon

Showing results (41-50 of 83) with videos related to

Pageof 9
Sort By:
Molecular Pharmacology|July 1, 1979
Quinazoline analogues of folic acid as inhibitors of thymidylate synthetase from bacterial and mammalian sourcesK J Scanlon, B A Moroson, J R Bertino, et al.
European Journal of Cancer (Oxford, England : 1990)|March 1, 1990
Differential oncogene amplification in tumor cells from a patient treated with cisplatin and 5-fluorouracilM Kashani-Sabet, Y Lu, L Leong, et al.
Nucleic Acids Research|March 1, 1996
Tissue-specific expression of an anti-ras ribozyme inhibits proliferation of human malignant melanoma cellsY Ohta, H Kijima, T Ohkawa, et al.
Molecular Urology|May 15, 2002
Hammerhead ribozymes as therapeutic agents for bladder cancerA Irie, M Kashani-Sabet, K J Scanlon, et al.
Cancer Research|May 15, 1995
Neoplastic reversion accomplished by high efficiency adenoviral-mediated delivery of an anti-ras ribozymeM Feng, G Cabrera, J Deshane, et al.
Chemotherapy|January 1, 1988
Mammary tumor and melanoma cell transport of PTT.119, a bis-(2-chloroethyl)amino-L-phenylalanine derivative with carrier amino acidsM J Yagi, K J Scanlon, S E Chin, et al.
Advances in Experimental Medicine and Biology|January 1, 1988
Mechanisms for cisplatin-FUra synergism and cisplatin resistance in human ovarian carcinoma cells both in vitro and in vivoK J Scanlon, Y Lu, M Kashani-Sabet, et al.
Cancer Communications|January 1, 1990
Potentiation of azidothymidine cytotoxicity in cisplatin-resistant human ovarian carcinoma cellsK J Scanlon, T Funato, B Pezeshki, et al.
Pharmacology & Therapeutics|January 1, 1995
Therapeutic applications of ribozymesH Kijima, H Ishida, T Ohkawa, et al.
Cancer Research|February 15, 1994
Suppression of the neoplastic phenotype in vivo by an anti-ras ribozymeM Kashani-Sabet, T Funato, V A Florenes, et al.
Pageof 9

Showing results (41-50 of 83) with videos related to

Sort By:
Pageof 9
Molecular Pharmacology|July 1, 1979
Quinazoline analogues of folic acid as inhibitors of thymidylate synthetase from bacterial and mammalian sourcesK J Scanlon, B A Moroson, J R Bertino, et al.
European Journal of Cancer (Oxford, England : 1990)|March 1, 1990
Differential oncogene amplification in tumor cells from a patient treated with cisplatin and 5-fluorouracilM Kashani-Sabet, Y Lu, L Leong, et al.
Nucleic Acids Research|March 1, 1996
Tissue-specific expression of an anti-ras ribozyme inhibits proliferation of human malignant melanoma cellsY Ohta, H Kijima, T Ohkawa, et al.
Molecular Urology|May 15, 2002
Hammerhead ribozymes as therapeutic agents for bladder cancerA Irie, M Kashani-Sabet, K J Scanlon, et al.
Cancer Research|May 15, 1995
Neoplastic reversion accomplished by high efficiency adenoviral-mediated delivery of an anti-ras ribozymeM Feng, G Cabrera, J Deshane, et al.
Chemotherapy|January 1, 1988
Mammary tumor and melanoma cell transport of PTT.119, a bis-(2-chloroethyl)amino-L-phenylalanine derivative with carrier amino acidsM J Yagi, K J Scanlon, S E Chin, et al.
Advances in Experimental Medicine and Biology|January 1, 1988
Mechanisms for cisplatin-FUra synergism and cisplatin resistance in human ovarian carcinoma cells both in vitro and in vivoK J Scanlon, Y Lu, M Kashani-Sabet, et al.
Cancer Communications|January 1, 1990
Potentiation of azidothymidine cytotoxicity in cisplatin-resistant human ovarian carcinoma cellsK J Scanlon, T Funato, B Pezeshki, et al.
Pharmacology & Therapeutics|January 1, 1995
Therapeutic applications of ribozymesH Kijima, H Ishida, T Ohkawa, et al.
Cancer Research|February 15, 1994
Suppression of the neoplastic phenotype in vivo by an anti-ras ribozymeM Kashani-Sabet, T Funato, V A Florenes, et al.
Pageof 9